SCHEMBL5010446

SCHEMBL5010446

CCCCN(C(=O)c1cc(NC(=O)c2cc(F)c(F)cc2Cl)[nH]n1)C1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.39
CNR1 P21554 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
GPR35 Q9HC97 1/20 0.39
GPR55 Q9Y2T6 1/20 0.39
GPR119 Q8TDV5 6/20 0.38
HTT P42858 1/20 0.37
RECQL P46063 1/20 0.37
ALDH1A1 P00352 2/20 0.37
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
DPP4 P27487 1/20 0.37
PARP1 P09874 1/20 0.37
PTBP1 P26599 1/20 0.37
THRB P10828 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
SCN9A Q15858 1/20 0.36
UBE2M P61081 1/20 0.36
DCUN1D1 Q96GG9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14587654 0.89 ALDH1A1 (0.47) HTTRECQLALDH1A1LMNASMN1; SMN2
SCHEMBL5013637 0.88 ALDH1A1 (0.39) HTTRECQLALDH1A1LMNASMN1; SMN2
SCHEMBL5013420 0.87 ALDH1A1 (0.38) HTTRECQLALDH1A1LMNASMN1; SMN2
SCHEMBL5013422 0.87 SMN1; SMN2 (0.40) NPSR1GPR55HTTRECQLALDH1A1
SCHEMBL5009754 0.85 NPC1 (0.42) HTTRECQLALDH1A1SMN1; SMN2KMT2A
SCHEMBL5008467 0.85 HTT (0.37) HTTRECQLALDH1A1LMNAPTBP1
SCHEMBL5008205 0.84 HTT (0.41) HTTRECQLALDH1A1SMN1; SMN2KMT2A
SCHEMBL5013415 0.83 HTT (0.39) HTTRECQLLMNASMN1; SMN2THRB
SCHEMBL14587658 0.82 ALDH1A1 (0.36) HTTRECQLALDH1A1LMNASMN1; SMN2
SCHEMBL14587659 0.81 ALDH1A1 (0.39) HTTRECQLALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US claimed
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL MAPT 4621/4885CNR1 2091/4885NPSR1 3984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.